Altogether, these studies using phosphoflow cytometry reveal that cancer patients, including those with melanoma and breast cancer, exhibit defects in IFN-α and IFN-γ signaling in their peripheral blood lymphocytes, which is evidenced by reduced activation of p-STAT1. This evidence concerns the gene IFNG and melanoma.